Topic

Bruce Liu is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

MBA from the University of Chicago, MSc in molecular biology from the University of Rochester, and BSc in biochemistry from Fudan University.

Tong Wang is a Senior Consultant in Simon-Kucher's Life Sciences division and is based in the Shanghai office. He has supported a breadth of projects, working with pharmaceutical and medical technology companies in the China and US markets. His experience includes launch strategies, P&MA strategies, reimbursement strategies, and market opportunity evaluation. MSc in bioengineering from Rice University and obtained his BSc in biomedical engineering from Shanghai Jiao Tong University.

 is a Senior Consultant with experience in a breadth of projects working with both pharmaceutical and medtech companies in US, EU and China markets. His experience includes launch strategy, P&MA strategy, reimbursement strategies and P&MA tool development. Ph.D. from The University of California, Los Angeles in Molecular Biology.

 is a Senior Consultant with experience in the pharmaceutical industry and healthcare policies. Her areas of specialty include pricing strategies, market access opportunities, as well as post-launch competitive positioning in China. Master's degree in public administration with major in policy research analysis from the University of Pittsburg and a Bachelor's degree in public health administration.

Articles

Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.

Improving Readiness for Volume-Based Procurement in China

New EU initiative aims to curve shortage of vaccines and therapies.

A FAB Opportunity Emerging for Europe’s Drugmakers

OM Pharma, active in the prevention of recurrent respiratory and urinary tract infections, wins the 2021 Geneva Economy Award.

OM Pharma Wins Geneva Economy Award

Sy Chyi Yeoh is Director of Business Development at regulatory and Pharmacovigilance service provider 

, part of global life science consultancy PLG (Product Life Group).

Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.

Harnessing China’s Global Opportunity

Chairman of the Harvard China Fund, Dr. William C. Kirby, talks about the potential impact on multinational western pharma firms of disruption in China.

What Happens to a Fortune 500’s 2025 Playbook If the China Market is Not Part of It?

Report claims an imbalance in influence of tech-transfer decisions.

Contention Swirls Around COVID Patent Waivers

Summits, proposals outline advice on response to future pandemics.

COVID Blame Games Give Way to Lesson Learning

Andaman7 and Afrisda, Inc. sign partnership agreement to support digital health implementation in Africa.

Africa Emerges as Digital Health Proving Ground

Pandemic triggers urgency around supply chain initiatives.

Bringing a European Focus to Drug  Import Vulnerabilities

Enoch Kariuki is the former CFO of VelosBio. He currently sits on the Board of Zentalis Pharmaceuticals and Imago Biosciences.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.